

ISSUE @ A GLANCE



Emerging causes and risk factors of heart failure: amyloidosis, myocarditis, immune checkpoint inhibitors, air pollution, and visceral adipose tissue

F. Crea

1533

CardioPulse

Music of the cosmos and the heart

L. Tonia, A. Stefanidis, N. Mparmpatzas, and B.A Popescu

1538

Hospital Ramón y Cajal, Madrid, Spain

R. Hinojar and J.L. Zamorano

1540

The Year in Cardiovascular Medicine 2020: Valvular Heart Disease

M. Nicholls

1542

Weekly Journal Scan

Cryoblation as first-line treatment of new-onset atrial fibrillation?

L. Galiuto and M. Volpe

1543

SPECIAL ARTICLES

European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions

C. Pristipino, P. Germonpré, D. Toni, H. Sievert, B. Meier, F. D'Ascenzo, S. Berti, E.M. Onorato, F. Bedogni, J.-L. Mas, P. Scacciatella, D. Hildick-Smith, F. Gaita, P.A Kyrle, J. Thomson, G. Derumeaux, D. Sibbing, M. Chessa, M. Hornung, J. Zamorano, and D. Dudek

1545

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

P. Garcia-Pavia, C. Rapezzi, Y. Adler, M. Arad, C. Basso, A. Brucato, I. Burazor, A.L.P. Caforio, T. Damy, U. Eriksson, M. Fontana, J.D. Gillmore, E. Gonzalez-Lopez, M. Grogan, S. Heymans, M. Imazio, I. Kindermann, A.V. Kristen, M.S. Maurer, G. Merlini, A. Pantazis, S. Pankuweit, A.G. Rigopoulos, and A. Linhart

1554

CLINICAL RESEARCH

Heart Failure and Cardiomyopathies

 **Temporal changes in total and hippocampal brain volume and cognitive function in patients with chronic heart failure—the COGNITION.MATTERS-HF cohort study**

A. Frey, G.A. Homola, C. Henneges, L. Mühlbauer, R. Sell, P. Kraft, M. Franke, C. Morbach, M. Vogt, W. Müllges, G. Ertl, L. Solymosi, L. Pirpamer, R. Schmidt, M. Pham, S. Störk, and G. Stoll

1569

Editorial

Heart failure, cognition, and brain damage


A. Villringer and U. Laufs

1579


Heart Failure and Cardiomyopathies

Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank
M. Wang, T. Zhou, Y. Song, X. Li, H. Ma, Y. Hu, Y. Heianza, and L. Qi


1582



The air pollution score, in a combination of $PM_{2.5}$, PM_{10} , $PM_{2.5-10}$, NO_2 , and NO_x , was associated with an increased risk of incident heart failure (HF) in a dose-response fashion.



The association between the air pollution score and HF was strengthened by the genetic susceptibility to HF.



Editorial

Air pollution and flooding in the lungs: modern insights into ancient problems

S. Rajagopalan, R.D. Brook, and S. Al-Kindi

1592

Heart Failure and Cardiomyopathies

Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction

H. Sorimachi, M. Obokata, N. Takahashi, Y.N.V. Reddy, C.C. Jain, F.H. Verbrugge, K.E. Koeppe, S. Khosla, M.D. Jensen, and B.A. Borlaug

1595

Editorial

Fighting HFrEF in women: taking aim at belly fat

C. Withaar, L.M.G. Meems, and R.A. de Boer


1606

Heart Failure and Cardiomyopathies

Myocarditis-associated necrotizing coronary vasculitis: incidence, cause, and outcome

A. Frustaci, M. Alfarano, R. Verardo, C. Agrati, R. Casetti, F. Miraldi, N. Galea, C. Letizia, and C. Chimenti

1609



Editorial

Myocarditis: endomyocardial biopsy and circulating anti-heart autoantibodies are key to diagnosis and personalized etiology-directed treatment

A.L.P. Caforio

1618

Heart Failure and Cardiomyopathies

The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study

M. D'Souza, D. Nielsen, I.M. Svane, K. Iversen, P.V. Rasmussen, C. Madelaine, E. Fosbøl, L. Køber, F. Gustafsson, C. Andersson, G. Gislason, C. Torp-Pedersen, and M. Schou

1621

Editorial

Are we underestimating the potential for cardiotoxicity related to immune checkpoint inhibitors?

M. Totzeck, E. Lutgens, and T.G. Neilan

1632

DISCUSSION FORUM

- Immune check point inhibitors are associated with a spectrum of cardiac events in patients with cancer
M. D'Souza, I.M. Svane, G. Gislason, and M. Schou

1636

- Cardiac events associated with immune checkpoint inhibitor therapy: the devil is in the detail
M.S. Anker, A.J.S. Coats, and S.D. Anker

1637

CARDIOVASCULAR FLASHLIGHT

- A novel deletion of the dystrophin gene in a patient without muscle-related symptoms

T. Sato, M. Wakita, M. Matsushima, and T. Sato

1638

- Delayed diffuse inflammatory myocardial damage in a child with a history of systemic inflammatory syndrome related to COVID-19

M. Mahdavi, G. Houshmand, H. Pouraliakbar, and G.M. Hejri

1639



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>



www.eurheartj.org